TY - JOUR
T1 - HIV drug development
T2 - The next 25 years
AU - Flexner, Charles
N1 - Funding Information:
This manuscript includes previously unpublished data from the AIDS Clinical Trials Group (ACTG) Protocol 223 (Figure 2a), and was supported in part by NIH grants AI‑27668, AI‑068636 and AI‑069465.
PY - 2007/12
Y1 - 2007/12
N2 - The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. Here we review the current treatment options, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we consider whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the potential impact of pharmacogenomics and individualized therapy.
AB - The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. Here we review the current treatment options, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we consider whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the potential impact of pharmacogenomics and individualized therapy.
UR - http://www.scopus.com/inward/record.url?scp=36749088862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36749088862&partnerID=8YFLogxK
U2 - 10.1038/nrd2336
DO - 10.1038/nrd2336
M3 - Review article
C2 - 17932493
AN - SCOPUS:36749088862
SN - 1474-1776
VL - 6
SP - 959
EP - 966
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 12
ER -